Business
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ETEnrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027.OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the seco
About this update from Ocugen, Inc.
[{"type":"image","alt":"Ocugen","displaySize":"","headline":null,"caption":"Ocugen","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":171,"url":"https://media.zenfs.com/en/globenewswire.com/11651bb9383edc87dda9630a4828404a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GdnYVqy165SQnz1CdcOk_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/11651bb9383edc87dda9630a4828404a","width":300,"height":171}},"lazy":false},{"type":"text","content":"Conference Call and Webcast Today at 8:30 a.m. ET","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027.","length":279,"tagName":"p"}]},{"val":[{"type":"text","content":"OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second quarter 2027 in advance of the BLA submission.","length":221,"tagName":"p"}]},{"val":[{"type":"text","content":"OCU410 positive preliminary Phase 2 data announced in January. Full Phase 2 data expected in March 2026. ","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"First regional licensing agreement for OCU400 in 2025 initiates strategic partnership strategy ahead of commercialization","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Rounded out executive leadership team with top talent in business development, commercial, finance, and operations to encompass all required expertise for upcoming growth","length":170,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":895,"olType":false},{"type":"text","content":"MALVERN, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported fourth quarter and full year 2025 financial results along with a general business update.","length":282,"tagName":"p"},{"type":"text","content":"“Considerable development across all our modifier gene therapy programs, notable licensing and financing agre...